Innovate UK is a government-backed agency supporting business-led innovation across the United Kingdom.
The investment round was led by Hiro Capital with participation from BoostVC, Maveron, and TenOneTen Ventures, alongside an innovation loan from Innovate UK.
"Over the last year, we have been redefining fitness and challenging people’s perceptions of what a fun and effective workout is, providing an alternative for people who want to keep fit but are unmotivated by the traditional fitness offerings"
The funding includes backing from Equity Gap, SIS Ventures, Alba Equity, the Scottish Investment Bank and Innovate UK.
"This is such an important milestone for Trojan Energy. Ever since we started this business, we have wanted to ensure that the benefits of the low carbon transition can be realised by everyone and not just those with a driveway. With this investment, our vision has moved a step closer. The rewards for our customers and our planet will be massive and prove the point that a big idea and great engineering can change the world."
The grant from Innovate UK is matched by recent seed backing from LifeArc, Parkwalk and UKI2S.
"Bringing validation of our novel gene therapy and the opportunity to accelerate the development of our pipeline, we are delighted to receive this grant from Innovate UK. Ikarovec believes its approach has great potential in the treatment of the debilitating disease of wet AMD, with significant advantages over existing therapies and those in development."
The mental health platform secured backing from the government agency to advance its technology and expand its team.
"We’re incredibly honoured and proud to have received this grant. Most of the funds will be used towards further development and content for the app as we have high expectations to deliver a platform that is contextually smart as well as impactful with practical, actionable steps and content."
The funding round was led by UCL Technology Fund, Parkwalk, and Innovate UK to support sensor development and clinical trials.
"Coronary heart disease is endemic worldwide but far too often the decision to implant a stent is based on sub-optimal information. Our technology addresses the ‘grey zone’ of patients where the requirement for a stent is currently difficult to determine. By using advanced optical sensing technology, we hope to significantly improve the accuracy of current treatments, saving healthcare costs and preventing unnecessary operations for patients that could be treated with medicines."
